Horace Mann Educators Corporation (FRA:HM9)

Inozyme Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	114.5	102.8	45	19.8	170.4	133.3
Depreciation & Amortization	26.8	26.4	26.2	27.6	18.4	23.4
Gain (Loss) on Sale of Investments	22.8	17.3	24	56.5	11	2.3
Stock-Based Compensation	10	9.9	9.5	8.9	8.4	6.7
Reinsurance Recoverable	36.3	55.7	-12.5	-309.8	7.4	1.6
Change in Income Taxes	15.8	28.2	-15	110.5	-91.2	8.3
Change in Insurance Reserves / Liabilities	141.7	82.8	186.7	334.2	114.5	69.9
Change in Other Net Operating Assets	131.4	93.5	52.7	-99.2	7.5	7
Operating Cash Flow	518.4	452.1	302.1	171.5	204.9	259.8
Operating Cash Flow Growth	78.64%	49.65%	76.15%	-16.30%	-21.13%	103.60%
Cash Acquisitions	-	-	-	-164.4	-	-
Investment in Securities	-121.4	-143	-116.6	-40.6	-291.8	-406.8
Other Investing Activities	10	7.2	9.2	-9.6	-10.2	-
Investing Cash Flow	-111.4	-135.8	-107.4	-214.6	-302	-406.8
Short-Term Debt Issued	-	2.5	-	9.9	114.3	7.3
Long-Term Debt Issued	-	-	297.7	-	5	4
Total Debt Issued	1.8	2.5	297.7	9.9	119.3	11.3
Total Debt Repaid	-513.7	-270	-441	-154	-416	-
Net Debt Issued (Repaid)	-511.9	-267.5	-143.3	-144.1	-296.7	11.3
Issuance of Common Stock	4	5.1	-	-	0.3	2.4
Repurchases of Common Stock	-11	-10.4	-8.3	-26.4	-7.3	-4.5
Common Dividends Paid	-55.9	-55.5	-53.9	-52.6	-51.4	-49.6
Other Financing Activities	-200.5	-150.4	-193.8	3.2	-39.2	-21.2
Financing Cash Flow	-397.1	-307.9	-207.8	-47.8	208.5	143.8
Net Cash Flow	9.9	8.4	-13.1	-90.9	111.4	-3.2
Cash Interest Paid	31.1	33.5	30.1	18.2	13.5	15.5
Cash Income Tax Paid	23	22.1	14	8.6	23.7	17.3
Levered Free Cash Flow	178.34	297.18	208.31	-545.89	-85.79	89.71
Unlevered Free Cash Flow	200.09	318.8	226.88	-533.76	-77.1	99.21
Change in Net Working Capital	-52.1	-180.5	-139.3	595.7	243.9	46.4

Source: S&P Global Market Intelligence. Insurance template. Financial Sources.